Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases

Journal of Controlled Release

Volumn 161, Issue 3, 2012, Pages 804-812

  Erster, Oran ^a   Thomas, Jerry M ^a   Hamzah, Juliana ^b   Jabaiah, Abeer M ^a   Getz, Jennifer A ^a   Schoep, Tobias D ^a   Hall, Sejal S ^a   Ruoslahti, Erkki ^b   Daugherty, Patrick S ^a  

^a University of California   (United States)

^b BURNHAM INSTITUTE   (United States)

Author keywords

Atherosclerosis; Pro antibody; Protease; Targeting; Vascular cell adhesion protein 1

Indexed keywords

ATHEROSCLEROSIS; PRO-ANTIBODY; PROTEASE; TARGETING; VASCULAR CELL ADHESION;

BINDING ENERGY; BLOOD VESSELS; CELL ADHESION; MAMMALS; TISSUE;

ANTIBODIES;

APOLIPOPROTEIN E; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE INHIBITOR; PROTEASE ACTIVATED ANTIBODY; PROTEINASE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BINDING AFFINITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; AORTA; APOLIPOPROTEINS E; CELL LINE; CORONARY ARTERY DISEASE; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HEK293 CELLS; HUMANS; MATRIX METALLOPROTEINASE 1; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; PRODRUGS; TISSUE DISTRIBUTION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84864614782     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.05.035     Document Type: Article

References (63)

1. L.M. Weiner, R. Surana, and S. Wang Monoclonal antibodies: versatile platforms for cancer immunotherapy Nat. Rev. Immunol. 10 5 2010 317 327
2. T.T. Hansel, H. Kropshofer, T. Singer, J.A. Mitchell, and A.J. George The safety and side effects of monoclonal antibodies Nat. Rev. Drug Discov. 9 4 2010 325 338
3. T.J. Giezen, A.K. Mantel-Teeuwisse, S.M. Straus, H. Schellekens, H.G. Leufkens, and A.C. Egberts Safety-related regulatory actions for biologicals approved in the United States and the European Union JAMA 300 16 2008 1887 1896
4. J.L. Li, A.M. Jubb, and A.L. Harris Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity Future Oncol. 6 7 2010 1099 1103
5. B.M. Tijink, J. Buter, R. de Bree, G. Giaccone, M.S. Lang, A. Staab, C.R. Leemans, and G.A. van Dongen A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus Clin. Cancer Res. 12 20 Pt 1 2006 6064 6072 (Pubitemid 44703770)
6. P. Haluska, F. Worden, D. Olmos, D. Yin, D. Schteingart, G.N. Batzel, M.L. Paccagnella, J.S. de Bono, A. Gualberto, and G.D. Hammer Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma Cancer Chemother. Pharmacol. 65 4 2009 765 773
7. C. Gridelli, A. Morabito, V. Gebbia, M. Mencoboni, F. Carrozza, M.G. Vigano, C. Verusio, R. Bollina, R. Mattioli, M.R. Valerio, G. Valmadre, P. Maione, A. Rossi, T. Cascone, F. Morgillo, M. Di Maio, M.C. Piccirillo, C. Gallo, F. Perrone, and F. Ciardiello Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials Lung Cancer 67 1 2009 86 92
8. S. Segaert, and E. Van Cutsem Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors Ann. Oncol. 16 9 2005 1425 1433 (Pubitemid 41222414)
9. T. Kamba, and D.M. McDonald Mechanisms of adverse effects of anti-VEGF therapy for cancer Br. J. Cancer 96 12 2007 1788 1795 (Pubitemid 46912024)
10. T. Bongartz, A.J. Sutton, M.J. Sweeting, I. Buchan, E.L. Matteson, and V. Montori Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA 295 19 2006 2275 2285 (Pubitemid 43736578)
11. E.A. Perez Cardiac toxicity of ErbB2-targeted therapies: what do we know? Clin. Breast Cancer 8 Suppl. 3 2008 S114 S120
12. M.K. Robinson, K.M. Hodge, E. Horak, A.L. Sundberg, M. Russeva, C.C. Shaller, M. von Mehren, I. Shchaveleva, H.H. Simmons, J.D. Marks, and G.P. Adams Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro Br. J. Cancer 99 9 2008 1415 1425
13. B. LeBerthon, L.A. Khawli, M. Alauddin, G.K. Miller, B.S. Charak, A. Mazumder, and A.L. Epstein Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate Cancer Res. 51 10 1991 2694 2698
14. K.N. Sugahara, T. Teesalu, P.P. Karmali, V.R. Kotamraju, L. Agemy, D.R. Greenwald, and E. Ruoslahti Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs Science 328 5981 2010 1031 1035
15. R. Weissleder, C.H. Tung, U. Mahmood, and A. Bogdanov Jr. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes Nat. Biotechnol. 17 4 1999 375 378 (Pubitemid 29166041)
16. A. Wunder, C.H. Tung, U. Muller-Ladner, R. Weissleder, and U. Mahmood In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response Arthritis Rheum. 50 8 2004 2459 2465 (Pubitemid 39062705)
17. F.A. Jaffer, D.E. Kim, L. Quinti, C.H. Tung, E. Aikawa, A.N. Pande, R.H. Kohler, G.P. Shi, P. Libby, and R. Weissleder Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor Circulation 115 17 2007 2292 2298 (Pubitemid 46685897)
18. L.B. Yang, K. Lindholm, R. Yan, M. Citron, W. Xia, X.L. Yang, T. Beach, L. Sue, P. Wong, D. Price, R. Li, and Y. Shen Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease Nat. Med. 9 1 2003 3 4 (Pubitemid 36098241)
19. J.M. Atkinson, C.S. Siller, and J.H. Gill Tumour endoproteases: the cutting edge of cancer drug delivery? Br. J. Pharmacol. 153 7 2008 1344 1352 (Pubitemid 351481504)
20. J.V. Frangioni New technologies for human cancer imaging J. Clin. Oncol. 26 24 2008 4012 4021
21. J. Chen, C.H. Tung, U. Mahmood, V. Ntziachristos, R. Gyurko, M.C. Fishman, P.L. Huang, and R. Weissleder In vivo imaging of proteolytic activity in atherosclerosis Circulation 105 23 2002 2766 2771 (Pubitemid 34615149)
22. C.M. Dollery, and P. Libby Atherosclerosis and proteinase activation Cardiovasc. Res. 69 3 2006 625 635 (Pubitemid 43139725)
23. P.K. Shah, E. Falk, J.J. Badimon, A. Fernandez-Ortiz, A. Mailhac, G. Villareal-Levy, J.T. Fallon, J. Regnstrom, and V. Fuster Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture Circulation 92 6 1995 1565 1569
24. M.J. Davies, J.L. Gordon, A.J. Gearing, R. Pigott, N. Woolf, D. Katz, and A. Kyriakopoulos The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis J. Pathol. 171 3 1993 223 229 (Pubitemid 23345967)
25. A.C. Lindsay, and R.P. Choudhury Form to function: current and future roles for atherosclerosis imaging in drug development Nat. Rev. Drug Discov. 7 6 2008 517 529 (Pubitemid 351767119)
26. Y. Nakashima, A.S. Plump, E.W. Raines, J.L. Breslow, and R. Ross ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree Arterioscler. Thromb. 14 1 1994 133 140
27. M.J. Casadaban, and S.N. Cohen Analysis of gene control signals by DNA fusion and cloning in Escherichia coli J. Mol. Biol. 138 2 1980 179 207 (Pubitemid 10044378)
28. A. Dienst, A. Grunow, M. Unruh, B. Rabausch, J.E. Nor, J.W. Fries, and C. Gottstein Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins J. Natl. Cancer Inst. 97 10 2005 733 747 (Pubitemid 40872380)
29. J.J. Rice, and P.S. Daugherty Directed evolution of a biterminal bacterial display scaffold enhances the display of diverse peptides Protein Eng. Des. Sel. 21 7 2008 435 442 (Pubitemid 351882133)
30. R.L. Reddick, S.H. Zhang, and N. Maeda Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression Arterioscler. Thromb. 14 1 1994 141 147
31. N. Maeda, L. Johnson, S. Kim, J. Hagaman, M. Friedman, and R. Reddick Anatomical differences and atherosclerosis in apolipoprotein E-deficient mice with 129/SvEv and C57BL/6 genetic backgrounds Atherosclerosis 195 1 2007 75 82 (Pubitemid 47561948)
32. P.S. Daugherty Protein engineering with bacterial display Curr. Opin. Struct. Biol. 17 4 2007 474 480 (Pubitemid 47451767)
33. S.S. Hall, and P.S. Daugherty Quantitative specificity-based display library screening identifies determinants of antibody-epitope binding specificity Protein Sci. 18 9 2009 1926 1934
34. K.T. Boulware Cellular libraries of peptide substrates (CLiPS): a high-throughput method for proteolytic enzyme characterization Chemical Engineering, vol. Ph.D. 2007 University of California Santa Barbara 123
35. G.M. Thurber, M.M. Schmidt, and K.D. Wittrup Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance Adv. Drug Deliv. Rev. 60 12 2008 1421 1434
36. C. Cheng, D. Tempel, R. van Haperen, L. van Damme, M. Algur, R. Krams, and R. de Crom Activation of MMP8 and MMP13 by angiotensin II correlates to severe intra-plaque hemorrhages and collagen breakdown in atherosclerotic lesions with a vulnerable phenotype Atherosclerosis 204 1 2009 26 33
37. D. Ma, W. Wu, G. Yang, J. Li, and Q. Ye Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors Bioorg. Med. Chem. Lett. 14 1 2004 47 50 (Pubitemid 38010191)
38. B.A. Kaufmann, J.M. Sanders, C. Davis, A. Xie, P. Aldred, I.J. Sarembock, and J.R. Lindner Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1 Circulation 116 3 2007 276 284 (Pubitemid 47196563)
39. M. Nahrendorf, F.A. Jaffer, K.A. Kelly, D.E. Sosnovik, E. Aikawa, P. Libby, and R. Weissleder Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis Circulation 114 14 2006 1504 1511 (Pubitemid 44527006)
40. M. Nahrendorf, E. Keliher, P. Panizzi, H. Zhang, S. Hembrador, J.L. Figueiredo, E. Aikawa, K. Kelly, P. Libby, and R. Weissleder 18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis JACC Cardiovasc. Imaging 2 10 2009 1213 1222
41. L.C. Hoyte, K.J. Brooks, S. Nagel, A. Akhtar, R. Chen, S. Mardiguian, M.A. McAteer, D.C. Anthony, R.P. Choudhury, A.M. Buchan, and N.R. Sibson Molecular magnetic resonance imaging of acute vascular cell adhesion molecule-1 expression in a mouse model of cerebral ischemia J. Cereb. Blood Flow Metab. 30 6 2010 1178 1187
42. G. Tekin, A. Tekin, I. Sipahi, A. Kaya, and V. Sansoy Plasma concentration of soluble vascular cell adhesion molecule-1 and oncoming cardiovascular risk in patients with unstable angina pectoris and non-ST-segment elevation myocardial infarction Am. J. Cardiol. 96 3 2005 379 381 (Pubitemid 41058863)
43. J.A. de Lemos, C.H. Hennekens, and P.M. Ridker Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk J. Am. Coll. Cardiol. 36 2 2000 423 426
44. G.K. Sukhova, U. Schonbeck, E. Rabkin, F.J. Schoen, A.R. Poole, R.C. Billinghurst, and P. Libby Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques Circulation 99 19 1999 2503 2509 (Pubitemid 29228279)
45. C.M. Dollery, J.R. McEwan, and A.M. Henney Matrix metalloproteinases and cardiovascular disease Circ. Res. 77 5 1995 863 868
46. A.C. Newby Metalloproteinases and vulnerable atherosclerotic plaques Trends Cardiovasc. Med. 17 8 2007 253 258 (Pubitemid 350087694)
47. V.M. Krishnamurthy, V. Semetey, P.J. Bracher, N. Shen, and G.M. Whitesides Dependence of effective molarity on linker length for an intramolecular protein-ligand system J. Am. Chem. Soc. 129 5 2007 1312 1320 (Pubitemid 46208603)
48. S. Kubetzko, C.A. Sarkar, and A. Pluckthun Protein PEGylation decreases observed target association rates via a dual blocking mechanism Mol. Pharmacol. 68 5 2005 1439 1454 (Pubitemid 41540000)
49. T. Wuest, E. Gerlach, D. Banerjee, J. Gerspach, D. Moosmayer, and K. Pfizenmaier TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor Oncogene 21 27 2002 4257 4265 (Pubitemid 34753832)
50. S.A. Lipton Pathologically activated therapeutics for neuroprotection Nat. Rev. Neurosci. 8 10 2007 803 808 (Pubitemid 47462118)
51. J. Rautio, H. Kumpulainen, T. Heimbach, R. Oliyai, D. Oh, T. Jarvinen, and J. Savolainen Prodrugs: design and clinical applications Nat. Rev. Drug Discov. 7 3 2008 255 270 (Pubitemid 351324639)
52. S.J. Thomas, and G.T. Grossberg Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias Clin. Interv. Aging 4 2009 367 377
53. W. Wu, Y. Luo, C. Sun, Y. Liu, P. Kuo, J. Varga, R. Xiang, R. Reisfeld, K.D. Janda, T.S. Edgington, and C. Liu Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms Cancer Res. 66 2 2006 970 980 (Pubitemid 43165965)
54. K.M. Bajjuri, Y. Liu, C. Liu, and S.C. Sinha The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity ChemMedChem 6 1 2011 54 59
55. R.A. Carter, I.K. Campbell, K.L. O'Donnel, and I.P. Wicks Vascular cell adhesion molecule-1 (VCAM-1) blockade in collagen-induced arthritis reduces joint involvement and alters B cell trafficking Clin. Exp. Immunol. 128 1 2002 44 51 (Pubitemid 34451178)
56. Q. Zhan, W. Yue, and H. Shaoshan The inhibitory effect of photodynamic therapy and of an anti-VCAM-1 monoclonal antibody on the in vivo growth of C6 glioma xenografts Braz. J. Med. Biol. Res. 44 5 2011 489 490
57. A. Soriano, A. Salas, M. Sans, M. Gironella, M. Elena, D.C. Anderson, J.M. Pique, and J. Panes VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice Lab. Invest. 80 10 2000 1541 1551
58. L. Chen, S.X. Lin, S. Amin, L. Overbergh, G. Maggiolino, and L.S. Chan VCAM-1 blockade delays disease onset, reduces disease severity and inflammatory cells in an atopic dermatitis model Immunol. Cell Biol. 88 3 2010 334 342
59. N.G. Wehner, G. Shopp, S. Oneda, and J. Clarke Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor Birth Defects Res. B Dev. Reprod. Toxicol. 86 2 2009 117 130
60. I.E. Krop, M. Beeram, S. Modi, S.F. Jones, S.N. Holden, W. Yu, S. Girish, J. Tibbitts, J.H. Yi, M.X. Sliwkowski, F. Jacobson, S.G. Lutzker, and H.A. Burris Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer J. Clin. Oncol. 28 16 2010 2698 2704
61. M.D. Galsky, M. Eisenberger, S. Moore-Cooper, W.K. Kelly, S.F. Slovin, A. DeLaCruz, Y. Lee, I.J. Webb, and H.I. Scher Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer J. Clin. Oncol. 26 13 2008 2147 2154
62. J. Bostrom, S.F. Yu, D. Kan, B.A. Appleton, C.V. Lee, K. Billeci, W. Man, F. Peale, S. Ross, C. Wiesmann, and G. Fuh Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site Science 323 5921 2009 1610 1614
63. A.M. Scott, F.T. Lee, N. Tebbutt, R. Herbertson, S.S. Gill, Z. Liu, E. Skrinos, C. Murone, T.H. Saunder, B. Chappell, A.T. Papenfuss, A.M. Poon, W. Hopkins, F.E. Smyth, D. MacGregor, L.M. Cher, A.A. Jungbluth, G. Ritter, M.W. Brechbiel, R. Murphy, A.W. Burgess, E.W. Hoffman, T.G. Johns, and L.J. Old A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors Proc. Natl. Acad. Sci. U. S. A. 104 10 2007 4071 4076 (Pubitemid 47181580)